These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10084469)

  • 61. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ; Jaeschke R
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006922. PubMed ID: 19588410
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.
    ZuWallack R; Adelglass J; Clifford DP; Duke SP; Wire PD; Faris M; Harding SM
    Chest; 2000 Aug; 118(2):303-12. PubMed ID: 10936117
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
    Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
    Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids.
    Kraft M; Martin RJ; Lazarus SC; Fahy JV; Boushey HA; Lemanske RF; Szefler SJ;
    Chest; 2003 Jul; 124(1):42-50. PubMed ID: 12853500
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Salmeterol does not cause tolerance during long-term asthma therapy.
    Arledge TE; Liddle R; Stahl E; Rossing TH
    J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1116-9. PubMed ID: 8977514
    [No Abstract]   [Full Text] [Related]  

  • 66. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma.
    Weiler JM; Nathan RA; Rupp NT; Kalberg CJ; Emmett A; Dorinsky PM
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):65-72. PubMed ID: 15702819
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007695. PubMed ID: 19821436
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
    Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
    Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I; Hall IP; McFarlane LC; Lipworth BJ
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
    O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
    Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.
    Wilson AM; Dempsey OJ; Sims EJ; Lipworth BJ
    Chest; 2001 Apr; 119(4):1021-6. PubMed ID: 11296164
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serum potassium levels, CPK-MB and ECG in children suffering asthma treated with beclomethasone or beclomethasone-salmeterol.
    Del Río-Navarro BE; Sienra-Monge JJ; Alvarez-Amador M; Reyes-Ruiz N; Arévalo-Salas A; Berber A
    Allergol Immunopathol (Madr); 2001; 29(1):16-21. PubMed ID: 11449530
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cause of death in the SMART Trial.
    Williams C
    Chest; 2006 Sep; 130(3):929-30; author reply 930. PubMed ID: 16963700
    [No Abstract]   [Full Text] [Related]  

  • 74. Effect of salmeterol and salmeterol plus beclomethasone on saliva flow and IgA in patients with moderate-persistent chronic asthma.
    del-Río-Navarro BE; Corona-Hernández L; Fragoso-Ríos R; Berber A; Torres-Alcántara S; Cuairán-Ruidíaz V; Sienra-Monge JJ
    Ann Allergy Asthma Immunol; 2001 Nov; 87(5):420-3. PubMed ID: 11730186
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sensitivity of quality of life domains and constructs to longitudinal change in a clinical trial comparing salmeterol with placebo in asthmatics.
    Hyland ME; Kenyon CA; Jacobs PA
    Qual Life Res; 1994 Apr; 3(2):121-6. PubMed ID: 7913852
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Salmeterol.
    Twentyman OP; Finnerty JP
    Lancet; 1991 May; 337(8749):1099. PubMed ID: 1673521
    [No Abstract]   [Full Text] [Related]  

  • 77. Nasal mucociliary clearance and salmeterol.
    Tay HL; Armoogum N; Tan LK
    Clin Otolaryngol Allied Sci; 1997 Feb; 22(1):68-70. PubMed ID: 9088685
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Implementing randomization procedures in the asthma clinical research network.
    Kunselman SJ; Armstrong TJ; Britton TB; Forand PE;
    Control Clin Trials; 2001 Dec; 22(6 Suppl):181S-95S. PubMed ID: 11728623
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients.
    Mann RD; Kubota K; Pearce G; Wilton L
    J Clin Epidemiol; 1996 Feb; 49(2):247-50. PubMed ID: 8606326
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recruitment strategies in the Asthma Clinical Research Network.
    Sorkness CA; Ford JG; Lemanske RF;
    Control Clin Trials; 2001 Dec; 22(6 Suppl):222S-35S. PubMed ID: 11728626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.